Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.
ENDRA Life Sciences Inc. (symbol: NDRA), is revolutionizing the field of ultrasound with its groundbreaking photo-acoustic solutions. The company’s innovations enable medical researchers to screen and modify disease models with unmatched quality and speed. ENDRA Life Sciences has established a global installed base of top-tier institutions utilizing their Nexus-128 system, the only comprehensive 3D imaging solution designed for imaging anatomy, physiology, and labeled molecular targets.
The Nexus 128 is a sophisticated preclinical photoacoustic computed tomography (CT) scanner tailored for small animal imaging. It facilitates quick, non-invasive quantification of physiological parameters, such as tumor vasculature, without the need for ionizing radiation. The fully 3D imaging technology of the Nexus 128 enhances sensitivity compared to traditional slice-based scanners, and its dynamic (4D) photoacoustic CT scans support advanced applications like quantification of probe uptake. Currently, leading imaging laboratories worldwide leverage the Nexus 128 for various research purposes.
Additionally, ENDRA Life Sciences is developing Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which aims to visualize tissue with MRI-like clarity but at a fraction of the cost and at the point of patient care. The TAEUS technology is designed to integrate with approximately 400,000 cart-based ultrasound systems in use globally. Initially, TAEUS focuses on measuring liver fat to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions affecting over a billion people worldwide, for which there are currently no effective diagnostic tools. Beyond liver applications, TAEUS is also being explored for several other clinical uses, such as visualizing tissue temperature during energy-based surgical procedures.
ENDRA Life Sciences continues to push the boundaries of medical imaging technology, collaborating with various partners to further enhance their solutions. Stay updated with the latest achievements, projects, and news from ENDRA Life Sciences to understand their impact and progression in the medical technology landscape.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced its financial results for Q4 and full year 2022, reporting a net loss of $3.3 million for Q4 2022, compared to a loss of $3.1 million in Q4 2021. For the entire year, the company recorded a net loss of $13.2 million, up from $11.2 million in 2021. Operating expenses increased to $3.3 million in Q4 2022 and $13.2 million for the year, primarily due to ongoing product development and commercialization efforts. ENDRA is pursuing FDA approval for its TAEUS liver device, having performed over 100 scans in 2022. The company has also extended its collaboration with GE HealthCare through December 2024.
FAQ
What is the current stock price of ENDRA Life Sciences (NDRA)?
What is the market cap of ENDRA Life Sciences (NDRA)?
What does ENDRA Life Sciences Inc. specialize in?
What is the Nexus-128 system?
What are the applications of the TAEUS technology?
Who uses the Nexus-128 system?
How does the Nexus-128 system benefit medical research?
What are NAFLD and NASH?
How is TAEUS technology integrated into existing ultrasound systems?
What makes ENDRA's imaging technology unique?
Are there other clinical applications for TAEUS technology?
Where can I find the latest news and updates about ENDRA Life Sciences?
